<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01526512</url>
  </required_header>
  <id_info>
    <org_study_id>metroCX</org_study_id>
    <nct_id>NCT01526512</nct_id>
  </id_info>
  <brief_title>Low Dose of Metronomic Cyclophosphamide and Capecitabine in Pretreated HER2-negative Metastatic Breast Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the role of low dose metronomic cyclophosphamide and
      capecitabine in pretreated metastatic breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Metronomic chemotherapy has been considered as an effective strategy in metastatic breast
      cancer. This trial is designed to evaluate the role of low dose metronomic cyclophosphamide
      and capecitabine in pretreated metastatic breast cancer.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">July 2013</completion_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biomarker</measure>
    <time_frame>6 weeks</time_frame>
    <description>Relationship of serum VEGF level and efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker</measure>
    <time_frame>6weeks</time_frame>
    <description>Relationship of immuno-marker(CD3,CD4,CD8,etc) and efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker</measure>
    <time_frame>1 time</time_frame>
    <description>Relationship of genetics(genetic polymorphisms) and efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>6 weeks</time_frame>
    <description>Overall Response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>6 weeks</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>3 weeks</time_frame>
    <description>Safety（NCI CTCAE v4.0）</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>metroCX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>metroCX Cyclophosphamide 50mg PO d1-28; Capecitabine 1500mg PO d1-28; every 28days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metroCX</intervention_name>
    <description>cyclophosphamide 50mg PO d1-28 capecitabine 1500mg PO d1-28; every 28days</description>
    <arm_group_label>metroCX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Females with age between 18 and 80 years old

          2. ECOG performance between 0-3

          3. Life expectancy more than 3 months

          4. Histological proven unresectable recurrent or advanced HER2-negative breast cancer

          5. At least one previous therapy regimen (including endocrine therapy) for metastatic
             breast cancer;suitable for monotherapy (Neoadjuvant or adjuvant docetaxel should be
             completed at least one year).

          6. At least one measurable disease according to the response evaluation criteria in solid
             tumor (RECIST1.1)

          7. No anticancer therapy within 4 weeks

          8. Adequate hematologic, hepatic, and renal function,No serious medical history of heart,
             lung, liver and kidney

          9. Provision of written informed consent prior to any study specific procedures

         10. Previous capecitabine is permitted, however, it should be completed at least 6 months.

        Exclusion Criteria:

          1. Pregnant or lactating women (female patients of child-bearing potential must have a
             negative serum pregnancy test within 14 days of first day of drug dosing, or, if
             positive, a pregnancy ruled out by ultrasound)

          2. Women of child-bearing potential, unwilling to use adequate contraceptive protection
             during the course of the study

          3. Treatment with an investigational product within 4 weeks before the first treatment

          4. Symptomatic central nervous system metastases

          5. Other active malignancies (including other hematologic malignancies) or other
             malignancies, except for cured nonmelanoma skin cancer or cervical intraepithelial
             neoplasia.

          6. Patient having a history of clinically significant cardiovascular, hepatic,
             respiratory or renal diseases, clinically significant hematological and endocrinal
             abnormalities, clinically significant neurological or psychiatric conditions

          7. Uncontrolled serious infection

          8. Patients with bad compliance

          9. Patients lack of Dihydropyrimidine Dehydrogenase(DPD)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhonghua Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leiping Wang, MD</last_name>
    <phone>+862164175590</phone>
    <email>leipingwang@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fudan University Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leiping Wang, MD</last_name>
      <phone>+862164175590</phone>
      <phone_ext>8908</phone_ext>
      <email>leipingwang@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2012</study_first_submitted>
  <study_first_submitted_qc>February 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2012</study_first_posted>
  <last_update_submitted>February 5, 2012</last_update_submitted>
  <last_update_submitted_qc>February 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>yanfei Liu</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Metronomic cyclophosphamide</keyword>
  <keyword>Metronomic capecitabine</keyword>
  <keyword>HER2-negative breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

